Sylvie Lorenzen

Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy – final results of the phase II RE-ExPEL study

BackgroundBased on results of prior trials (TAGS, REGARD, RAINBOW), it seems promising to combine Ramucirumab (Ram) beyond progression (PD) with TAS-102 (trifluridine/tipiracil). The purp...

Alexander Stein ;

Timorshah Habibzada ;

Peter Herhaus ;

E. Goekkurt ;

Disorn Sookthai ;

Tanita Brulin ;

Kristina Ihrig ;

Claudia Pauligk ;

Salah-Eddin Al-Batran , MD;

Sylvie Lorenzen ;

Thorsten Goetze ;

06/25/2023

Management of Upper GI Cancers in the Elderly

Sylvie Lorenzen ;

07/07/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Sylvie Lorenzen

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products